Pancreatic Cancer Research

ResearcherNara Medical UniversityNo recent work listed

Kimihiko Kichikawa

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5002830709. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
18
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 1 paper · 2014: none · 2015: 4 papers · 2016: 3 papers · 2017: none · 2018: 1 paper · 2019: 3 papers

Papers 14

  1. Risk Factors for Late-Onset Gastrointestinal Hemorrhage After Pancreatoduodenectomy for Pancreatic Cancer. Co-author DOI 10.1007/s00268-018-4791-7↗
  2. A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Ca… Co-author DOI 10.1007/s00268-018-4820-6↗
  3. Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.05.461↗
  4. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-018-1709-7↗
  5. Adjuvant Hepatic Arterial Infusion Chemotherapy After Resection for Pancreatic Cancer Using Coaxial Catheter-Port System Compared with Conventional System. Last author DOI 10.1007/s00270-016-1292-7↗
  6. Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer. Last author DOI 10.1007/s00330-015-3999-2↗
  7. Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2015.10.034↗
  8. Importance of resectability status in neoadjuvant treatment for pancreatic cancer. Co-author DOI 10.1002/jhbp.258↗
  9. Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. Co-author DOI 10.1007/s00268-015-3205-3↗
  10. Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. Co-author DOI 10.1007/s00423-015-1304-0↗
  11. Impact of Smoking on Pancreatic Cancer Patients Receiving Current Chemotherapy. Co-author DOI 10.1097/mpa.0000000000000395↗
  12. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. Co-author DOI 10.1007/s00534-012-0532-8↗
  13. Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer. Co-author DOI 10.1007/s00534-010-0336-7↗
  14. Intra-arterial chemoinfusion prior to chemoradiotherapy with full-dose systemic gemcitabine for management of locally advanced pancreatic cancer. Last author PMID 22110218↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masayuki Sho · 14 shared papers, 2011–2019 · strength 0.78
  2. Takahiro Akahori · 12 shared papers, 2011–2019 · strength 0.70
  3. Toshihiro Tanaka · 11 shared papers, 2011–2019 · strength 0.62
  4. Minako Nagai · 9 shared papers, 2015–2019 · strength 0.58
  5. Hideyuki Nishiofuku · 10 shared papers, 2011–2019 · strength 0.52
  6. Satoshi Nishiwada · 7 shared papers, 2015–2019 · strength 0.45
  7. Yoshiyuki Nakajima · 10 shared papers, 2011–2016 · strength 0.44
  8. Chiho Ohbayashi · 6 shared papers, 2015–2019 · strength 0.36
  9. Kota Nakamura · 4 shared papers, 2018–2019 · strength 0.34
  10. Kenji Nakagawa · 4 shared papers, 2018–2019 · strength 0.34
  11. Naoya Ikeda · 4 shared papers, 2018–2019 · strength 0.34
  12. Shoichi Kinoshita · 6 shared papers, 2013–2016 · strength 0.27
  13. Tadataka Takagi · 1 shared paper, 2019 · strength 0.09
  14. Hitoshi Yoshiji · 1 shared paper, 2019 · strength 0.08
  15. Chihiro Kawaguchi · 2 shared papers, 2013–2015 · strength 0.08
  16. Satoshi Yasuda · 2 shared papers, 2013–2015 · strength 0.08
  17. Ichiro Yamato · 2 shared papers, 2011–2013 · strength 0.05
  18. Aya Hashimoto · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.